Details for Patent: 8,613,950

Which drugs does patent 8,613,950 protect, and when does it expire?

Patent 8,613,950 protects STAXYN and is included in one NDA.

This patent has fifty-three patent family members in thirty-eight countries.

Summary for Patent: 8,613,950

Title:	Pharmaceutical forms with improved pharmacokinetic properties
Abstract:	The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.
Inventor(s):	Serno; Peter (Gladbach, DE), Heinig; Roland (Wuppertal, DE), Pauli; Kerstin (Dortmund, DE), Hayauchi; Yutaka (Leverkusen, DE)
Assignee:	Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:	11/885,019
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,613,950
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 8,613,950

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,613,950

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2005 009 240	Mar 1, 2005

PCT Information
PCT Filed	February 16, 2006	PCT Application Number:	PCT/EP2006/001393
PCT Publication Date:	September 08, 2006	PCT Publication Number:	WO2006/092207

International Family Members for US Patent 8,613,950

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	053552
Argentina	111572
Austria	E552828
Australia	2006220100
Brazil	PI0609375
Canada	2599617